title: Expression and functional heterogeneity of chemokine receptors CXCR4 and CXCR7 in primary patient-derived glioblastoma cells.
abstract: Glioblastoma (GBM) is the most common primary brain tumor in adults. The poor prognosis and minimally successful treatments of these tumors indicates a need to identify new therapeutic targets. Therapy resistance of GBMs is attributed to heterogeneity of the glioblastoma due to genetic alterations and functional subpopulations. Chemokine receptors CXCR4 and CXCR7 play important roles in progression of various cancers although the specific functions of the CXCL12-CXCR4-CXCR7 axis in GBM are less characterized. In this study we examined the expression and function of CXCR4 and CXCR7 in four primary patient-derived GBM cell lines of the proliferative subclass, investigating their roles in in vitro growth, migration, sphere and tube formation. CXCR4 and CXCR7 cell surface expression was heterogeneous both between and within each cell line examined, which was not reflected by RT-PCR analysis. Variable percentages of CXCR4+CXCR7- (CXCR4 single positive), CXCR4-CXCR7+ (CXCR7 single positive), CXCR4+CXCR7+ (double positive), and CXCR4-CXCR7- (double negative) subpopulations were evident across the lines examined. A subpopulation of slow cell cycling cells was enriched in CXCR4 and CXCR7. CXCR4+, CXCR7+, and CXCR4+/CXCR7+ subpopulations were able to initiate intracranial tumors in vivo. CXCL12 stimulated in vitro cell growth, migration, sphere formation and tube formation in some lines and, depending on the response, the effects were mediated by either CXCR4 or CXCR7. Collectively, our results indicate a high level of heterogeneity in both the surface expression and functions of CXCR4 and CXCR7 in primary human GBM cells of the proliferative subclass. Should targeting of CXCR4 and CXCR7 provide clinical benefits to GBM patients, a personalized treatment approach should be considered given the differential expression and functions of these receptors in GBM.
authors.affiliation: Department of Pharmacology & Therapeutics, College of Medicine, University of Florida, Gainesville, Florida, United States of America.
authors.forename: Che
authors.initials: C
authors.lastname: Liu
authors.forename: Kien
authors.initials: K
authors.lastname: Pham
authors.forename: Defang
authors.initials: D
authors.lastname: Luo
authors.forename: Brent A
authors.initials: BA
authors.lastname: Reynolds
authors.forename: Parvinder
authors.initials: P
authors.lastname: Hothi
authors.forename: Gregory
authors.initials: G
authors.lastname: Foltz
authors.forename: Jeffrey K
authors.initials: JK
authors.lastname: Harrison
mesh_terms: D000818:Animals; D017209:Apoptosis; D001932:Brain Neoplasms / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism; D002465:Cell Movement; D049109:Cell Proliferation; D054377:Chemokine CXCL12 / Q000494:pharmacology; D005434:Flow Cytometry; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D005909:Glioblastoma / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D054387:Receptors, CXCR / Q000378:metabolism*; D019718:Receptors, CXCR4 / Q000378:metabolism*
chemical_list: C501896:ACKR3 protein, human; C515255:CXCL12 protein, human; C527276:CXCR4 protein, human; D054377:Chemokine CXCL12; D054387:Receptors, CXCR; D019718:Receptors, CXCR4
references.citation: Int J Cancer. 2005 Oct 20;117(1):82-9
references.pmid: 15880586
references.citation: Cell Immunol. 2012;272(2):230-41
references.pmid: 22070874
references.citation: Oncogene. 2010 Aug 12;29(32):4599-610
references.pmid: 20531309
references.citation: Integr Biol (Camb). 2010 Nov;2(11-12):680-6
references.pmid: 20871938
references.citation: Nature. 2010 Dec 9;468(7325):824-8
references.pmid: 21102434
references.citation: J Biol Chem. 2003 Jan 3;278(1):257-62
references.pmid: 12414810
references.citation: J Neurooncol. 2011 Jun;103(2):231-8
references.pmid: 20820869
references.citation: Blood. 2009 Jun 11;113(24):6085-93
references.pmid: 19380869
references.citation: Blood. 2012 May 24;119(21):4908-18
references.pmid: 22496149
references.citation: Oncogene. 2012 Nov 8;31(45):4750-8
references.pmid: 22266857
references.citation: J Exp Med. 2006 Sep 4;203(9):2201-13
references.pmid: 16940167
references.citation: Neurosurgery. 2008 Sep;63(3):560-9; discussion 569-70
references.pmid: 18812968
references.citation: Mol Endocrinol. 2003 May;17(5):792-803
references.pmid: 12586845
references.citation: Eur J Haematol. 2010 Dec;85(6):472-83
references.pmid: 20887389
references.citation: Oncogene. 2003 Apr 17;22(15):2361-73
references.pmid: 12700671
references.citation: Cancer Cell. 2010 Jan 19;17(1):98-110
references.pmid: 20129251
references.citation: Clin Cancer Res. 2000 Sep;6(9):3530-5
references.pmid: 10999740
references.citation: Glia. 2012 Mar;60(3):372-81
references.pmid: 22083878
references.citation: Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8
references.pmid: 14595012
references.citation: Cancer Lett. 2006 Jul 8;238(1):30-41
references.pmid: 16046252
references.citation: N Engl J Med. 2005 Mar 10;352(10):997-1003
references.pmid: 15758010
references.citation: J Virol. 2012 Jan;86(2):854-64
references.pmid: 22090104
references.citation: Cancer Biol Ther. 2011 Jan 15;11(2):242-53
references.pmid: 21084856
references.citation: Glia. 2011 Apr;59(4):590-602
references.pmid: 21294158
references.citation: Cancer Res. 2011 Nov 1;71(21):6643-53
references.pmid: 21900396
references.citation: J Biol Chem. 2011 Sep 16;286(37):32188-97
references.pmid: 21730065
references.citation: Brain. 2011 May;134(Pt 5):1331-43
references.pmid: 21515906
references.citation: Oncotarget. 2012 Oct;3(10):1124-36
references.pmid: 23165409
references.citation: Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15735-40
references.pmid: 17898181
references.citation: Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):628-32
references.pmid: 20018651
references.citation: Nature. 2010 Dec 9;468(7325):829-33
references.pmid: 21102433
references.citation: Cancer Res. 2007 Jan 15;67(2):651-8
references.pmid: 17234775
references.citation: Cancer Res. 2003 Jul 1;63(13):3833-9
references.pmid: 12839981
references.citation: Glia. 2011 Aug;59(8):1190-9
references.pmid: 21446051
references.citation: PLoS One. 2010 Feb 11;5(2):e9175
references.pmid: 20161793
references.citation: Cancer Res. 2003 Apr 15;63(8):1969-74
references.pmid: 12702590
references.citation: Cell Prolif. 2003 Apr;36(2):75-86
references.pmid: 12680875
references.citation: Neuron. 2011 Jan 13;69(1):77-90
references.pmid: 21220100
references.citation: Cancer Res. 2002 Jun 1;62(11):3106-12
references.pmid: 12036921
references.citation: Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4274-80
references.pmid: 21262804
references.citation: Neuron. 2011 Jan 13;69(1):61-76
references.pmid: 21220099
references.citation: Clin Exp Metastasis. 2008;25(3):201-11
references.pmid: 18071913
references.citation: Cancer Cell. 2006 Mar;9(3):157-73
references.pmid: 16530701
references.citation: Cancer Res. 2010 Apr 15;70(8):3299-308
references.pmid: 20388803
references.citation: Cancer Res. 2005 Jul 1;65(13):5864-71
references.pmid: 15994964
references.citation: J Pathol. 2011 Jul;224(3):344-54
references.pmid: 21618540
references.citation: J Cell Biochem. 2008 Jan 1;103(1):245-55
references.pmid: 17549698